# Casma Therapeutics > Clinical-stage biotechnology company founded in 2018 and headquartered in Boston, MA, developing cellular degradation medicines built on the autophagy pathway. Its PHLYT (Phagosome-Lysosome Targeting) platform initiates target-specific autophagic degradation of disease targets independent of size or complexity — organelles, protein aggregates and large signaling complexes — across oncology, inflammation, neurodegeneration and metabolic disease. Casma Therapeutics publishes no public developer API, developer portal, SDK, MCP server or machine-readable API contract. This file describes the company's public web surface only. ## Company - [Casma Therapeutics](https://www.casmatx.com/): Company home page. - [About us](https://www.casmatx.com/about/): Founding, mission, vision, and company story. - [The science: autophagy](https://www.casmatx.com/science/): How autophagy works and why it matters therapeutically. - [Platform & pipeline](https://www.casmatx.com/platform-pipeline/): The PHLYT platform and program pipeline. - [Our team](https://www.casmatx.com/our-team/): Leadership and scientific team. - [Investors](https://www.casmatx.com/investors/): Investor information. - [Careers & culture](https://www.casmatx.com/careers-culture/): Open roles and company culture. ## News - [News & media](https://www.casmatx.com/news-media/): Press releases and company announcements. ## Legal - [Privacy Policy](https://www.casmatx.com/privacy-policy/) - [Terms of use](https://www.casmatx.com/terms-of-use/) ## Contact - [Contact us](https://www.casmatx.com/contact-us/): Casma Therapeutics, Inc, 201 Brookline Ave, Suite 1401, Boston, MA 02215 — contact@casmatx.com ## Catalog - [APIs.json](https://raw.githubusercontent.com/api-evangelist/casma-therapeutics/refs/heads/main/apis.yml): API Evangelist network profile for Casma Therapeutics.